J. Erjefalt (Lund, Sweden), C. Von Garnier (Bern, Switzerland)
LATE-BREAKING ABSTRACT: The CCR4 Antagonist CCX6239 for the treatment of allergic airways disease
Z. Miao, Y. Wang, L. Manmohan, Y. Wang, J. Kalisiak, J. Powers, M. Walters, D. Daniel, L. Seitz, T. Sullivan, T. Schall (Mountain View, United States Of America)
|  |
Repeated IL-4 stimulation impairs STAT1 signaling and confers CD4+ T cell resistance to IL-27-mediated suppression
Z. Chen, S. Wang, C. Bai, H. Huang (Shanghai, China; Denver, United States Of America)
|   |
QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects
J. Arm, I. Bottoli, A. Skerjanec, A. Groenewegen, P. Lowe, S. Maahs (Cambridge, East Hanover, United States Of America; Basel, Switzerland)
| |
Effect of bariatric surgery on asthma: 12 months follow-up
A. van Huisstede, M. Castro Cabezas, H. Zengerink, R. Luitwieler, C. Taube, P. Hiemstra, G. J. Braunstahl (Rotterdam, Leiden, Netherlands)
| |
Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma
S. Wenzel, J. Ming, J. Hamilton, A. Radin, R. Rocklin, T. Hultsch, L. Wang, F. Skobieranda, G. Pirozzi (Pittsburgh, Bridgewater, Tarrytown, Cambridge, United States Of America)
| |
Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial
R. Djukanovic, S. Wilson, M. Castro, R. Leigh, E. R. Sutherland, J. Canvin, G. Peachey, J. Ackrill, P. Georgiou, C. W. Chen (Southampton, Horsham, United Kingdom; St Louis, Denver, East Hanover, United States Of America; Calgary, Canada)
| |
Cytokine patterns and latent viruses in patients with severe asthma and COPD
A. Konishcheva, V. Gervazieva (Moscow, Russian Federation)
| |
Tiotropium for uncontrolled asthma (a meta-analysis)
M. Jorge, R. E. Villalobos, M. G. Yu, C. V. Uy (Manila, Philippines)
| |